2.Surgical management of gastrointestinal stromal tumors.
Chinese Journal of Gastrointestinal Surgery 2007;10(1):5-7
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumor of the gastrointestinal tract. GISTs have characteristic by a specific histological and immunohistochemical pattern. Malignant biological behaviors should be paid more attention in treatment. At present, operation is still the most important treatment method for GISTs. For patients with primary, localized GISTs, surgery represents the only chance of cure. The principle of surgery is complete resection of visible and microscopic lesions. Special care needs to be taken to avoid capsule rupture and intra-abdominal spillage, which increase the risk of recurrence. Positive resection margins may result in a higher risk of local and peritoneal relapse. Every effort should be taken to achieve negative margins. Although wide margins have not been shown to be beneficial, an en bloc resection is still recommended, when GISTs are densely adherent to adjacent organs. As GISTs rarely metastasize to lymph nodes, lymphadenectomy is not routinely indicated. While laparoscopic resection of GISTs is technically possible, it should only be undertaken when it will not increase the chance of tumor rupture. The success of imatinib in the treatment of recurrent and metastatic GISTs have prompted investigation into the adjuvant treatment for the significant risk of recurrence of GISTs and neo-adjuvant treatment for unresectable cases. Combined complete surgical resection and molecular therapy are the new therapy model which will improve therapeutic effect.
Gastrointestinal Stromal Tumors
;
surgery
;
Humans
3.Clinical observation on effect of biological agent etanercept cmbined with methotrexate in treatment of refractory rheumatoid arthritis
Chongqing Medicine 2013;(26):3100-3101,3104
Objective To investigate the clinical effect of biological agents etanercept combined with methotrexate in the treat-ment of refractory rheumatoid arthritis .Methods 30 cases of refractory rheumatoid arthritis treated in January 2010 to January 2012 were selected and randomly divided into the two groups ,15 cases in each group .The control group was treated with oral meth-otrexate(MTX) 15 mg per week ,and the combined treatment group was treated with the biological agent etanercept 12 .5-25 .0 mg by subcutaneous injection ,twice per week ,combined with M TX15 mg per week .3 months were taken as a course of treatment .Re-sults The effective rates of ACR20 ,ACR50 and ACR70 in the combined treatment group were 73 .3% ,46 .7% and 26 .7% respec-tively ,which were significantly higher than those in the control group (P<0 .01) .4 cases in the combined treatment group appeared gastrointestinal discomfort .Conclusion Biological agent etanercept combined with M TX in the treatment of refractory rheumatoid arthritis has better clinical curative effect .
4.Experiment of the effect and safety of mdr1 gene transferring into k562 cells
Journal of Chongqing Medical University 1986;0(03):-
Objective:To transfer full-length human mdrlcDNA into K562 cells and assess the feasibility and safety in vitro.Methods:PA317 cells were transducted via a virus vector,pHaMDR1/A,containing full-length human mdr1cDNA by calcium phosphate precipitation.The K562 cells were infected with the virus supernatant.The transfection rate was determined by using CFU selection,FACS and SP immunohistochemical methods respectively.The foreign Pgp function was tested by MTT assay and DNR exclusion with FACS analysis .The cellular cycle and the expression of bcl-2 and c-myc gene were detected by using CFU sclcction,FACS and SP immunohistochemical mcthods respcctively.The forcign Pgp function was tested by MTT assay and DNR exclusion with FACS analysis.The cellular cycle and the expression of bcl-2 and c-myc gene were detected by using PI via FCM and SP stain respectively.These data were analyzed with statistic graph and T-test for match pairs.Results:①The highest transfection rate of K562/MDR6-18 cells were 34%,even up to 84% after colchicine selection.②The exogenous Pgp expression of K562/MDR6-18 cells lasted for more than 4 months with a slow decrease after 10 generations.③The exogenous Pgp got an exclusive pump function.④K562/MDR6-18 cells appeared 1.46-2.22 times cross multidrug resistance phenotype.⑤K562/MDR6-18 cellular proliferation showed a mild,short,restored change.There was no abnormal apoptosis or proliferation.Conclusions:It implies a feasible,attractive and safe way that mdr1 gene transfers into target cells to get exogenous effective MDR.They also provide the basic protocol for using mdr1 gene modifying bone marrow transplantation against the myelosuppressive effects of anticancer drugs.
5.Clinical research on the treatment of teratoma in individual patient
Journal of Chongqing Medical University 1986;0(02):-
Objective:To explore the stratege of teratoma treatment in individual patient.Methods:53 cases(40 benign and 13 malignant) with teratoma were admitted from January 2001 to October 2003.Benign teratomas were treated with individual operation process in order to resect the whole tumor and to keep the function of the organ.In malignant teratoma chemotherapy was given before operation,then,tumor resection,and individual chemotherapy after operation.Results:40 benign cases treated with operation were all successful without complications except 3 newborn babies with low serum albumin and delayed wound healing.In 13 malignant cases,5 abdicated chemotherapy and 8 succeeded continuously with individual chemotherapy postoperation.Until now:initial lose to follow -up 5 examples,midway lose to follow -up 2 examples,PR3,CR3.Conclusion:It's important that the individual treatment of teratoma,especially individual chemotherapy against malignant teratoma can improve quality of life and increase cure rate in children with tumor.
6.Case of anal pain caused by lumbar disc herniation.
Tian YE ; Chu MENG ; Shan-shan WANG
Chinese Acupuncture & Moxibustion 2014;34(4):346-346
7.Progress of the Research on the Structure and Bioactivities of Marine Microbial Exopolysaccharide
Shan-Shan ZHANG ; Chang-Yun WANG ;
Microbiology 1992;0(01):-
It is significant for theory and application to study on marine microbial exopolysaccharides with differential structures and activities endowed by the specific marine environment.The recent progress of the research on the structures and bioactivities of marine microbial ex- opolysaccharides was reviewed,and the prospect of the research and development of the marine microbial exopolysaecharides was also expec- ted.
8.Dose-effect of HIFU in tumor therapy
Journal of International Oncology 2011;38(7):503-505
HIFU is a new technology of noninvasive tumorectomy, which take use of thermal effects, mechanical effects and cavitation effects, etc. Currently, One of the difficulties in clinical application is how to determine energy dose of HIFU and resulted biological change. This paper expounds the factors such as sound intensity, irradiation duration, treatment depth, sound environment,etc. ,which affect energy input and therapeutic efficiency in HIFU treatment.
9.Proto-oncogene Bmi-1 and head and neck cancer
Journal of International Oncology 2013;40(9):665-668
Bmi-1 is a core member of the polycomb group genes.As a proto-oncogene,Bmi-1 plays an important role in cell self-renewal,proliferation and apoptosis.Several studies have shown that Bmi-1 is highly expressed in some head and neck malignant tumors,such as nasopharyngeal cancer and laryngeal carcinoma.Furthermore,the expression level of Bmi-1 is closely related to the occurrence,development,incursion and prognosis of tumor.Bmi-1 is expected to become a novel tumor molecular marker,and provides a new direction for the treatment of the head and neck malignant tumor.
10.Progress in immunotherapy for gastric cancer
Chinese Journal of Digestive Surgery 2010;09(4):247-249
Gastric cancer is one of the most common malignancies in China. Currently, surgical resection, chemotherapy and radiotherapy are still the main therapeutic methods.The postoperative 5-year survival of patients with gastric cancer is lower than 60%. As a means of adjuvant therapy, immunotherapy has the potential to improve the survival of patients with gastric cancer, because its therapeutic targeting and toxicity profile does not overlap with those of conventional therapies. The effector cells of the immune system (T, B and NK cells), when activated, are able to lyse and destroy tumor cells through specific recognition of tumor-associated antigens. However, most immunotherapy research in gastric cancer is still limited to the preclinical stage due to the weakness of its antigenicity. With the development of tumor immunobiology and genetic engineering, immunotherapy has become the focus of research for the treatment of gastric cancer.